News

Hims & Hers’ ugly split with Wegovy maker weighs on the telehealth company’s future

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market ...

Wegovy maker warns of slower profits as rivals bite

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Wegovy maker Novo's profit warning triggers $70 billion share rout

Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on ...

Novo Nordisk Shares Plummet as Wegovy Knockoffs Weigh on Sales

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Explore more

Is your Wegovy real? Here’s how to ID fake weight loss drugs

GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...

New data show most patients now stay on Wegovy, Zepbound after a year

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.